Lansoprazol Actavis

Lansoprazole, the active ingredient in Lansoprazol Actavis, is a proton pump inhibitor presented as an oral dosage form for systemic use. It reduces gastric acid production and is used to treat conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease, Helicobacter pylori infection regimens and Zollinger‑Ellison syndrome in adult patients.

GNH USA supplies Lansoprazol Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazol Actavis, a proton pump inhibitor, is employed in the management of acid‑related gastrointestinal disorders. - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief by decreasing esophageal acid exposure. - Peptic ulcer disease: promotes ulcer healing through sustained acid suppression. - Helicobacter pylori eradication regimens: enhances antibiotic effectiveness by creating a less acidic gastric environment. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors.

Lansoprazole may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild, transient pain in the head. - Diarrhea: loose stools occurring during treatment. - Abdominal pain: discomfort or cramping in the stomach area. - Nausea: feeling of sickness or urge to vomit. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: serious skin blistering and detachment. - Hepatic enzyme elevation: increased liver transaminases indicating liver stress. - Hypomagnesemia: low serum magnesium leading to muscle cramps or cardiac arrhythmia.

Before initiating Lansoprazol Actavis, consider the following precautions to ensure safe use. - Assess renal function: dose adjustment may be required in severe impairment. - Use cautiously in the elderly: higher incidence of fractures and infections reported. - Monitor for opportunistic infections: prolonged acid suppression can predispose to pneumonia or gastrointestinal infections. - Avoid abrupt discontinuation: tapering may reduce risk of rebound acid hypersecretion. - Review concomitant medications: potential interactions may affect drug levels. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lansoprazole can affect the pharmacokinetics of several medicines; interactions are classified by clinical significance.

Major Interactions (Avoid): - Atazanavir: reduced absorption leading to loss of antiviral efficacy. - Ketoconazole: markedly decreased antifungal exposure. - Clopidogrel: impaired activation resulting in reduced antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in anticoagulant effect, monitor INR. - Digoxin: may increase serum levels, observe for toxicity. - Methotrexate: reduced renal clearance, watch for toxicity. - HIV protease inhibitors (e.g., ritonavir): altered plasma concentrations, adjust dosing as needed.